Analystreport

Jounce Therapeutics, Inc. (NASDAQ: JNCE) had its price target lowered by analysts at Roth Capital from $28.00 to $15.00. They now have a "buy" rating on the stock.

Jounce Therapeutics, Inc.  (JNCE) 
Last jounce therapeutics, inc. earnings: 2/27 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.jouncetx.com